@entity4258 in the treatment of XXXX .

@entity1 @entity6835 @entity1680 @entity66 @entity799 @entity4258 @entity294 @entity2348 @entity869 @entity204 @entity526 @entity1536
@entity66 are a major cause of illness and @entity204 among @entity1 and young @entity1 , especially in developing countries. They are also the principal cause of illness in tourists who travel to these countries. Overall, the main causes of @entity294 are bacterial. Campylobacter, enteropathogenic @entity526 , @entity6835 and enterotoxigenic @entity526 are, in this order, the most common bacterial enteropathogens isolated in developing countries, and campylobacter and @entity6835 in developed countries. Even though the cornerstone of the treatment of @entity294 is oral rehydration, especially in @entity1 , the better knowledge of the pathogens involved and the mechanisms by which these organisms produce @entity294 has brought the reconsideration of antibiotic use, which just a few years ago was considered unnecessary except for @entity6835 . The increasing number of @entity6835 and @entity1680 resistant to @entity869 and @entity799 and the recognition of campylobacter, an enteropathogen normally resistant to these drugs as a major cause of @entity294 , makes it necessary to investigate new agents against these three enteropathogens. Antimicrobial susceptibility studies done in Mexico and other parts of the world have shown that @entity4258 , a new @entity1536 , is very active against multi-resistant @entity1680 and @entity6835 and against campylobacter, with MIC values of approximately 0.8 mg/l. Furthermore, it achieves high concentrations in faeces after oral administration. Clinical studies of @entity4258 used in inflammatory @entity294 and in prophylaxis of traveller's @entity294 have demonstrated it to be an effective and well-tolerated drug. @entity4258 has great potential for the treatment of @entity2348 reflected by its broad in vitro activity as well as its effectiveness in initial clinical trials.(ABSTRACT TRUNCATED AT 250 WORDS)
